Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for May, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Credit rating agency A.M. Best Co. affirmed the issuer credit rating (ICR) of Coventry Health Care Inc. ( ) at “bbb-”. The rating agency also reiterated all the debt ratings of the company.
Additionally, A. M. Best raised the financial strength rating (FSR) of Coventry’s subsidiaries – Coventry Health Care of Iowa Inc. and Coventry Health Care of Illinois Inc. – to “A-” from “B++” and the ICR of the subsidiaries to “a-” from “bbb+”. The rating agency also raised the FSR of two other subsidiaries - Coventry Health Care of Louisiana Inc. and Coventry Health Care of Delaware Inc. – to “A-” from B+” and their ICRs to “a-” from “bbb-”.
The FSR and ICR of Coventry Health Care of Kansas Inc. were also raised to “A-” and “a-” from “B++” and “bbb”, respectively. A. M. Best also raised the FSR of three other subsidiaries - Coventry Health Care of Florida Inc., Coventry Health Plan of Florida Inc. and Coventry Summit Health Plan Inc. – to “B+” from “B” and ICR to “bbb-“ from “bb-“.
Enhanced operating efficiency and expanding membership base of another subsidiary, HealthCare USA of Missouri LLC, led to reaffirmation of its FSR at “B++” and upgradation of its ICR to “bbb+” from “bbb”. Meanwhile, improved underwriting trend and satisfactory capitalization of OmniCare Health Plan Inc. prompted A. M. Best to upgrade the subsidiary’s FSR to “B++” from “B+” and ICR to “bbb” from “bbb-“.
A. M. Best has a stable outlook on all the ratings, indicating low possibility of any rating change in the near term.
Earlier this week, Coventry cancelled its agreement with Sequenom Inc. ( SQNM - Snapshot Report ) to provide coverage for the latter’s MaterniT21 PLUS test to its 2.2 million policyholders. Sequenom’s subsidiary, Sequenom Center for Molecular Medicine LLC, had signed a provider network participation agreementwith Coventry on May 4, 2012, effective July 1, 2012.
However, on May 14, 2012, Coventry cancelled the agreement without citing any reason. The company will stop its overage of Sequenom’s tests from August 31, 2012.
Coventry currently carries a Zacks #5 Rank, which translates into a short-term ‘Strong Sell’ rating.
Read the full Snapshot Report on SQNM